Abstract:Background A higher circulating plasma ceramide ratio (C16:0/C24:0) is associated with an increased risk of heart failure, even after accounting for standard risk factors including lipid markers. However, the pathobiological mechanisms that underlie this association are incompletely understood. We tested the hypothesis that plasma ceramide ratio (C16:0/C24:0) is associated with adverse cardiac remodeling in the community. Methods and Results We evaluated 2652 Framingham Offspring Study participants (mean age, 66±9 years; 55% women) who attended their eighth examination cycle and underwent routine echocardiography and liquid chromatography–tandem mass spectrometry–based assays for circulating ceramide concentrations. We used multivariable linear regression models to relate C16:0/C24:0 (independent variable) to the following echocardiographic measures (dependent variables; separate models for each): left ventricular mass, left ventricular ejection fraction, left atrial emptying fraction, left atrial end‐systolic volume, E/e′ (a measure of left ventricular diastolic function), and left ventricular global circumferential and longitudinal strain by speckle‐tracking echocardiography. In multivariable‐adjusted analyses, higher C16:0/C24:0 per standard deviation increment was associated with lower left ventricular ejection fraction (0.991‐fold change in left ventricular ejection fraction; P =0.0004), worse global circumferential strain (β=0.34, P =0.004), higher left atrial end‐systolic volume (β=2.48, p<0.0001), and lower left atrial emptying fraction (0.99‐fold change; P <0.0001). The C16:0/C24:0 ratio was not associated with either E/e′ or global longitudinal strain, and the association with higher left ventricular mass was rendered statistically nonsignificant upon correction for multiple comparisons. Conclusions Our cross‐sectional observations in a large community‐based sample are consistent with a potential detrimental impact of higher ceramide ratio (C16:0/24:0) on cardiac remodeling traits, which may partly explain the associations of these molecular species with clinical heart failure. Clinical Perspective What Is New? We used a high‐throughput liquid chromatography–mass spectrometry assay to quantify ratios of ceramide molecular species in the plasma and subsequently assessed their relations to echocardiographic measures of cardiac remodeling. Data from the Framingham Offspring Study demonstrate that higher plasma ceramide ratio (C16:0/24:0) is associated with potentially detrimental changes in echocardiographic measures of cardiac structure and function. What Are the Clinical Implications? Our study observations support the notion that the association between higher ceramide ratio (C16:0/24:0) and the subsequently increased risk of clinical heart failure may be partly explained by relations with unfavorable subclinical cardiac structural and functional alterations. Introduction Heart failure (HF) remains a leading cause of morbidity and mortality, affecting 6.5 million Americans, and its prevalence is expected to rise with the aging of the US population. 1 Given the substantial and rising burden of HF, ongoing efforts are needed to uncover novel mechanistic pathways that may underlie disease pathogenesis and progression. One area of recent interest is the role of plasma ceramide biomarkers in the pathogenesis of cardiovascular disease (CVD), including HF. Ceramides are bioactive lipids with a sphingoid base and a fatty acyl chain that are present in cell membranes and plasma, and have major influences on cellular signaling, differentiation, senescence, and programmed cell death. 2 Ceramide synthases facilitate variable acetylation of the sphingoid base, producing a spectrum of ceramide molecular species. 2 Expression and biomolecular effects of ceramides can vary on the basis of detectable relative proportions of distinct circulating ceramide species and the CVD risk profile. 3 Recent studies have focused, therefore, on analyzing the ratio of select ceramides, such as the ratio of long‐chain to very‐long‐chain ceramide species. 4 , <a class="tab-link" hre -Abstract Truncated-

Associations of NAFLD with circulating ceramides and impaired glycemia

ASSA13-10-11 Nonalcoholic Fatty Liver Disease is Associated with Subclinical Atherosclerosis

Association Between Serum Free Fatty Acid Levels and Nonalcoholic Fatty Liver Disease: a Cross-Sectional Study

Association of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes: Clinical Features and Independent Risk Factors in Diabetic Fatty Liver Patients.

Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes mellitus: the Dallas Heart Study

Elevated serum ceramides are linked with obesity-associated gut dysbiosis and impaired glucose metabolism

Ceramide as a Mediator of Non-Alcoholic Fatty Liver Disease and Associated Atherosclerosis

Association between nonalcoholic fatty liver disease and increased glucose-to-albumin ratio in adults without diabetes

Non-alcoholic Fatty Liver Disease Is Associated With Cardiovascular Outcomes in Subjects With Prediabetes and Diabetes: A Prospective Community-Based Cohort Study

Effect of circulating ceramides on adiposity and insulin resistance in patients with type 2 diabetes: An observational cross‐sectional study

Advanced Fibrosis Associates with Atherosclerosis in Subjects with Nonalcoholic Fatty Liver Disease.

Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study

The Association Between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999–2004

Carotid Intima-Media Thickness in Indian Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and a Meta-Analysis

Plasma Ceramides Are Elevated in Obese Subjects with Type 2 Diabetes and Correlate with the Severity of Insulin Resistance.

Liver Fat Content, Evaluated Through Semi-Quantitative Ultrasound Measurement, is Associated with Impaired Glucose Profiles: A Community-Based Study in Chinese

Nonalcoholic fatty liver disease is associated with coronary artery calcium score in diabetes patients with higher HbA1c

Abstract 13791: Non-Alcoholic Fatty Liver Disease Risk SNP Variants Affect Lipid Metabolism

Association of Circulating Ceramides With Cardiac Structure and Function in the Community: The Framingham Heart Study.

The Relation of Biomarkers in Serum Non-Alcohol Fatty Liver Disease with Diabetes Mellitus Type 2 and NAFLD Obese among Adults in Basrah Governorate

Atherosclerosis and Associated Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome